CL2022001130A1 - Moléculas de fusión del ecd de siglec-9 y métodos de uso de estas - Google Patents

Moléculas de fusión del ecd de siglec-9 y métodos de uso de estas

Info

Publication number
CL2022001130A1
CL2022001130A1 CL2022001130A CL2022001130A CL2022001130A1 CL 2022001130 A1 CL2022001130 A1 CL 2022001130A1 CL 2022001130 A CL2022001130 A CL 2022001130A CL 2022001130 A CL2022001130 A CL 2022001130A CL 2022001130 A1 CL2022001130 A1 CL 2022001130A1
Authority
CL
Chile
Prior art keywords
siglec
methods
fusion molecules
ecd fusion
ecd
Prior art date
Application number
CL2022001130A
Other languages
English (en)
Inventor
Spencer Liang
Samuel Nalle
Jeonghoon Sun
Hua Long
Rashmi Bankoti
Original Assignee
Alector Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alector Llc filed Critical Alector Llc
Publication of CL2022001130A1 publication Critical patent/CL2022001130A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Recrystallisation Techniques (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • External Artificial Organs (AREA)

Abstract

La presente descripción se refiere generalmente al ECD de Siglec-9 o moléculas de fusión del ECD de Siglec-9, y a métodos de tratamiento que usan ECD de Siglec-9 y moléculas de fusión del ECD de Siglec-9.
CL2022001130A 2019-11-04 2022-05-02 Moléculas de fusión del ecd de siglec-9 y métodos de uso de estas CL2022001130A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962930227P 2019-11-04 2019-11-04
US202063014940P 2020-04-24 2020-04-24
US202063092753P 2020-10-16 2020-10-16

Publications (1)

Publication Number Publication Date
CL2022001130A1 true CL2022001130A1 (es) 2023-02-24

Family

ID=73598983

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001130A CL2022001130A1 (es) 2019-11-04 2022-05-02 Moléculas de fusión del ecd de siglec-9 y métodos de uso de estas

Country Status (17)

Country Link
US (1) US11987612B2 (es)
EP (1) EP4055031A2 (es)
JP (1) JP2022553571A (es)
KR (1) KR20220092918A (es)
CN (1) CN114667298A (es)
AU (1) AU2020378251A1 (es)
BR (1) BR112022008321A2 (es)
CA (1) CA3155345A1 (es)
CL (1) CL2022001130A1 (es)
CO (1) CO2022005587A2 (es)
CR (1) CR20220244A (es)
EC (1) ECSP22044316A (es)
IL (1) IL292499A (es)
MX (1) MX2022005376A (es)
PE (1) PE20221271A1 (es)
TW (1) TW202132329A (es)
WO (1) WO2021091885A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022013388A (es) 2020-04-24 2022-11-30 Bayer Ag Aminotiazoles sustituidos como inhibidores de dgkzeta para la activacion inmune.
WO2024102635A1 (en) * 2022-11-07 2024-05-16 Alector Llc Uses of siglec-9 ecd fusion molecules in cancer treatment

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
AU2003301882A1 (en) 2002-11-01 2004-06-07 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
BRPI0613361A2 (pt) 2005-07-01 2011-01-04 Medarex Inc anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1
GB0521991D0 (en) 2005-10-28 2005-12-07 Univ Dundee Siglec-9 binding agents
WO2007120815A2 (en) 2006-04-12 2007-10-25 The Regents Of The University Of California Methods for treating lymphocyte-associated disorders by modulation of siglec activity
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
HUE051954T2 (hu) 2011-11-28 2021-03-29 Merck Patent Gmbh ANTI-PD-L1 ellenanyagok és alkalmazásaik
CN104302665B (zh) 2011-12-21 2019-04-23 安姆根有限公司 与新生儿Fc受体的结合增强的变体Fc多肽
WO2014098249A1 (ja) 2012-12-21 2014-06-26 国立大学法人名古屋大学 組織修復活性組成物及びその利用
WO2014120642A1 (en) 2013-01-30 2014-08-07 The General Hospital Corporation Diagnosis and treatment of hepatorenal syndrome
JP2017532025A (ja) 2014-09-10 2017-11-02 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 交差反応性ｓｉｇｌｅｃ抗体
JP7340221B2 (ja) 2015-05-01 2023-09-07 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニア グリカン依存性免疫療法分子
JP7060502B2 (ja) 2015-10-29 2022-04-26 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－９抗体及びその使用方法
WO2017075342A1 (en) 2015-10-30 2017-05-04 Hach Company Storage stable standards for aqueous chlorine analysis
WO2017085166A1 (en) 2015-11-17 2017-05-26 Innate Pharma Siglec-10 antibodies
WO2017123745A1 (en) 2016-01-12 2017-07-20 Palleon Pharma Inc. Use of siglec-7 or siglec-9 antibodies for the treatment of cancer
KR102398425B1 (ko) 2016-03-08 2022-05-16 이나뜨 파르마 에스.에이. Siglec 중화 항체
GB201611535D0 (en) 2016-07-01 2016-08-17 King's College London Methods and compositions for treating cancer with siglec-9 activity modulators
CN109414490A (zh) 2016-07-01 2019-03-01 小利兰·斯坦福大学理事会 抑制性免疫受体抑制方法和组合物
EP3652207A1 (en) 2017-07-10 2020-05-20 Innate Pharma Combination therapy using antibody to human siglec-9 and antibody to human nkg2a for treating cancer
CA3066514A1 (en) 2017-07-10 2019-01-17 Innate Pharma Siglec-9-neutralizing antibodies
EP3802582A4 (en) 2018-06-07 2022-06-15 Palleon Pharmaceuticals Inc. MULTIMERIC PROTEINS FOR DETECTING A CARBOHYDRATE AND/OR TREATMENT OF A SIGLEC MEDIATED DISORDER
WO2020006385A2 (en) 2018-06-29 2020-01-02 Verseau Therapeutics, Inc. Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof
WO2020072593A1 (en) 2018-10-02 2020-04-09 Obi Pharma, Inc. Combination therapy using anti-ssea-4 antibody in combination with therapeutic oncology agents
WO2020212986A1 (en) 2019-04-17 2020-10-22 Bar-Ilan University Siglec-based chimeric polypeptides and uses thereof
CA3142433A1 (en) 2019-06-04 2020-12-10 Verseau Therapeutics, Inc. Anti-siglec-9 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
US20220283165A1 (en) 2019-07-12 2022-09-08 The Board Of Trustees Of The Leland Stanford Junior University Methods of Enhancing Immunogenicity of Cancers

Also Published As

Publication number Publication date
IL292499A (en) 2022-06-01
WO2021091885A3 (en) 2021-06-17
PE20221271A1 (es) 2022-09-01
JP2022553571A (ja) 2022-12-23
KR20220092918A (ko) 2022-07-04
US11987612B2 (en) 2024-05-21
BR112022008321A2 (pt) 2022-07-26
TW202132329A (zh) 2021-09-01
CN114667298A (zh) 2022-06-24
CR20220244A (es) 2022-06-28
US20210284710A1 (en) 2021-09-16
CO2022005587A2 (es) 2022-07-29
CA3155345A1 (en) 2021-05-14
WO2021091885A2 (en) 2021-05-14
EP4055031A2 (en) 2022-09-14
ECSP22044316A (es) 2022-07-29
MX2022005376A (es) 2022-05-19
AU2020378251A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
CL2019002824A1 (es) Anticuerpos anti-lag3.
CL2022000036A1 (es) Polipéptidos modificados y usos de los mismos (divisional de solicitud no. 201900261)
CO2017009060A2 (es) Polipéptido hibrido de la enzima de degradación inmunoglobulina g del s. pyogenes y enzima de degradación de inmunoglobulina g del streptococcus equi ssp. zooepidemicus
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
DOP2020000245A (es) Anticuerpos il-11
DOP2020000021A (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y métodos de uso de anticuerpos anti-cd39
BR112019004998A2 (pt) anticorpos anti-pd-1(cd279)
GT201700081A (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
CL2022001130A1 (es) Moléculas de fusión del ecd de siglec-9 y métodos de uso de estas
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
PH12020552229A1 (en) Il-11ra antibodies
CL2023001550A1 (es) Sistemas activos dinámicos acromosómicos.
BR112017017284A2 (pt) protease de cisteína
BR112017023868A2 (pt) anticorpos anti-itga3, anticorpos anti-itga3 ativáveis, e métodos de uso dos mesmos
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
BR112019005139A2 (pt) anticorpos anti-il-33 e usos dos mesmos
AU2016263598A8 (en) Methods and kits for treating depression
BR112017016897A2 (pt) cepas fúngicas e métodos de uso
BR112018000187A2 (pt) composto, composição, método, e, uso de um composto ou composição
CL2016002827A1 (es) Sistema para limpiar una región ocular, que comprende a un aplicardor que consiste de una primera y segunda camara, un elemento sellable que divide la primera y segunda camara, donde la segunda camara contiene una composicion ocular y b un surtidor kit y metodos de tratamientos.
BR112018070188A2 (pt) uso de caulim como opacificante
BR112022003956A2 (pt) Anticorpos anti-cd73
BR112021021645A2 (pt) Anticorpos anti-hvem e uso dos mesmos.
BR112017020896A2 (pt) variantes de protoxina-ii e métodos de uso
CR20190471A (es) Moduladores de la expresión de pcsk9